Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2016

View Archived Issues

XT-150 as a potential solution for opioid abuse crisis

Array BioPharma and Asahi Kasei Pharma establish strategic collaboration in pain and inflammation

Morphotek and AREVA Med to investigate ontuxizumab conjugated with lead-212

Astellas announces a new collaborative research agreement with AIST

Astellas and LEO Pharma announce the closing of transaction to transfer global dermatology business

Janssen discontinues phase III development of fulranumab for osteoarthritis pain

Guizhou Bailing Group Pharmaceutical discloses alpha-glucosidase inhibitors

Active Biotech patents S100A9 inhibitors

Bristol-Myers Squibb presents peroxidase inhibitors

Eli Lilly develops PDE4B inhibitors

Calreticulin antibody useful in the assessment of bone marrow biopsies

Array BioPharma discontinues MILO study of binimetinib

Amicus' migalastat gets positive opinion from EMA for Fabry disease

EMA's CHMP backs approval of Trevicta for schizophrenia

Samsung Bioepis' infliximab biosimilar receives positive opinion in E.U.

Positive interim results obtained in phase III trial of masitinib in ALS

CHMP recommends approval of Strimvelis for ADA-SCID

BMS's acquisition of Padlock Therapeutics completed

Xilonix will undergo accelerated assessment in E.U.

APE1 and MTH1 may be useful biomarkers for the diagnosis of breast cancer

IXICO announces two milestones concerning its Parkinson's disease franchise

Meiji Seika Pharma receives marketing rights for Ultibro and Seebri from Novartis Pharma in Japan

EMA committee recommends approval of pandemic influenza vaccine

Bionomics begins phase I trial for BNC-101 in metastatic colorectal cancer

CHMP supports E.U. approval of daratumumab

Acetylon Pharmaceuticals reports HDAC6 inhibitors

New bromodomain inhibitor shows promising preclinical results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...